U.S. regulator says too many drugmakers chasing same cancer strategy

CHICAGO (Reuters) - A new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S. regulator says too many companies are focused on the same approach.

from Reuters: Science News http://ift.tt/1ZDDTg9
via IFTTT